Sera Prognostics, Inc. (SERA)
NASDAQ: SERA · Real-Time Price · USD
3.440
-0.040 (-1.15%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Company Description
Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States.
The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother’s risk of delivering spontaneously.
It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction.
The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Sera Prognostics, Inc.
| Country | United States |
| Founded | 2008 |
| IPO Date | Jul 15, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 64 |
| CEO | Evguenia Lindgardt |
Contact Details
Address: 2749 East Parleys Way, Suite 200 Salt Lake City, Utah 84109 United States | |
| Phone | 801 990 0520 |
| Website | sera.com |
Stock Details
| Ticker Symbol | SERA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001534969 |
| CUSIP Number | 81749D107 |
| ISIN Number | US81749D1072 |
| Employer ID | 26-1911522 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Evguenia Lindgardt M.B.A. | President, Chief Executive Officer and Director |
| Austin Aerts | Chief Financial Officer |
| Dr. John J. Boniface Ph.D. | Chief Scientific Officer |
| Dr. Gregory C. Critchfield M.D., M.S. | Executive Director |
| Robert G. Harrison | Chief Information Officer |
| Benjamin G. Jackson J.D. | General Counsel |
| Dr. Paul Kearney Ph.D. | Chief Data Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | ARS | Filing |
| Apr 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 8, 2025 | 144 | Filing |
| Mar 19, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 19, 2025 | 10-K | Annual Report |
| Mar 19, 2025 | 8-K | Current Report |
| Mar 10, 2025 | 144 | Filing |
| Mar 10, 2025 | 144 | Filing |
| Mar 7, 2025 | 144 | Filing |